Immune checkpoint inhibitors (ICIs) have transformed oncology, enabling patients with previously untreatable malignancies to achieve durable responses. However, as the use of agents such as ...

HIDRADENITIS suppurativa may newly develop or flare in some patients receiving immune checkpoint inhibitor therapy.

Building Capacity for Research on Cancer, Older Adults, and Under-Represented Populations: Methods and Lessons Learned From the Development of the University of Maryland Marlene and Stewart Greenebaum ...

Immune checkpoint inhibitor colitis is a common immune-related adverse event associated with immunotherapy and may be refractory to corticosteroids and biologic therapy. Evidence guiding management ...

Checkpoint inhibitors are a groundbreaking class of cancer treatment, but they come with two frustrating challenges. In some cases, tumors show no initial response, rendering the therapy ineffective ...

Skin cancers, lung cancers, lymphomas—though these cancers affect different parts of the body, they can all be treated with one of the latest therapies medicine has to offer: checkpoint inhibitors.

Boehringer Ingelheim is offering up to $1.3 billion for Nerio Therapeutics and a preclinical immune checkpoint inhibitor program that the German pharma giant hopes will become the “centerpiece” of its ...

Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. Sun Pharma has agreed to purchase the Massachusetts biotech for an upfront value of ...